Biogen partners with Octave Bioscience for MS study

US commercial stage precision-care company Octave Bioscience has announced plans to conduct an observational, real-world study with biotech major Biogen (Nasdaq: BIIB) as the sponsor.

The study will utilize the Octave Precision Care Solution (Octave Solution) to evaluate 150 patients with multiple sclerosis (MS) at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s (OMRF) MS Center of Excellence, and Orlando Health MS Comprehensive Care Center. Octave’s Solution provides neurologists and their patients with quantitative, objective metrics to facilitate informed care and shared decision-making to provide a more personalized MS care approach.

"We believe this study will illustrate the power of the full Octave Solution - insights from biological, radiographic, and clinical phenotype tools - to create a dynamic, longitudinal perspective of a patient with MS," said William Hagstrom, Octave’s founder and chief executive, adding: "The initiation of this study marks an important milestone as we work with one of the leading companies in MS and neuroscience to obtain deeper insights about patients and their treatments, and ultimately enable improved care for these patients."